NeuroVive: large shareholder to participate in the rights issue
NeuroVive Pharmaceutical AB (publ) announces that Baulos Capital Belgium SA, one of the largest shareholders, intends to participate in the upcoming rights issue.
Press releases
NeuroVive publishes prospectus and announces new publication date of the Q1 interim report
On 28 February 2016, the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive") decided to carry out a new issue of shares and warrants (units) with preferential rights for the company ...
NeuroVive strengthens its organization with the recruitment of Cecilia Hofvander as IR and Communications Director
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has recruited Cecilia Hofvander as Investor Relations and Communications Director effective from 1 June 2016 i ...
NeuroVive Pharmaceutical publishes 2015 annual report
NeuroVive Pharmaceutical AB (publ) today announced that the English version of the annual report for 2015 is now available on the company's website www.neurovive.com. The annual report can also be acc ...
NeuroVive Pharmaceutical AB (publ): report from EGM
Today, 31 March 2016, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company"). A summary of the resolutions follows. All resolutions were passed ...
Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)
The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 4 p.m. on Thursday, 28 April 2016 at Medicon V ...
NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation
NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, announces that the independent safety committee has once again endorsed the continuation of the ongoing Phase II CiPRICS (Ci ...
Notice of extraordinary general meeting in NeuroVive Pharmaceutical AB (publ)
The shareholders in NeuroVive Pharmaceutical AB (publ) reg. no. 556595-6538 (the "Company") are hereby convened to the extraordinary general meeting, held at 10.00 a.m. on Thursday, 31 March 2016 at ...
NeuroVive resolves on rights issue totaling approximately SEK 94.4 million for continued development of the project portfolio
On 28 February 2016, The Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") decided to carry out a new issue of shares and warrants (units) with preferential right ...
NeuroVive Pharmaceutical AB (publ) – amendment number of shares and votes
Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of share issue in kind conducted by NeuroVive Pharmaceutical AB ...
Board Selects New CEO Erik Kinnman to Lead NeuroVive
NeuroVive Pharmaceutical AB (publ) board of directors is pleased to announce that it has selected Erik Kinnman as NeuroVive's Chief Executive Officer (CEO). Erik Kinnman will assume the new role on th ...
NeuroVive: Year-End Report 1 Jan. 2015 – 31 Dec. 2015
Fourth Quarter (1 Oct. 2015 - 31 Dec. 2015) · Net revenues were SEK 0 (0) and other operating income was SEK 23,000 (8,000). · Loss before tax was SEK -7,366,000 (-17,346,000). · Earnings per share* w ...